Fredun Pharmaceuticals
- Market cap
- ₹ 2,242 Cr.
- P/E
- 57.5x
- P/B
- 8.27x
- 52-week range
- 1,195.2 – 1,665
- ROE
- 16%
- ROCE
- 21%
- Dividend yield
- 0%
- Debt / equity
- 0.87
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Fredun Pharmaceuticals Ltd. is an India-based pharmaceuticals formulation manufacturing company. The Company is engaged in manufacturing dietary/herbal supplements, nutraceuticals, and other healthcare products, along with animal healthcare products. Its segment includes Fredun Generics, Pet Care, Nutraceuticals, Cosmeceuticals and Mobility. Its Generics Division, marketed under the Fredun Gx brand. The Pet Healthcare segment operates under the Freossi brand. The Nutraceutical Division under Fredun Nutrition brand. Its Cosmeceuticals Division, operating under the Bird N Beauty (BNB) and Beautyfred brands, is focused on skincare and personal care products. Its Mobility Division, operating under Chuu Balm, BraceOn, NebOn, and DigiOn, caters to the ortho rehabilitation aids and pain management market. It offers a range of products, including antihypertensive, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It also provides comprehensive pet care technology platforms.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Fredun Pharmaceuticals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)57.5 against a typical 34.6: pricier than most peers (1st = cheapest).164th of 220
- Sales growth+90% against a typical +15.6% from a year earlier.18th of 197
- Profit growth+85.7% against a typical +18.9% from a year earlier.36th of 160
- Size₹ 2,241.9 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).67th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Moderate safety, with caution
Rated BBB+ by Infomerics- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| Infomerics | IVR BBB+ | Stable | 31 Mar 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 31 Mar 2026 | Reaffirmed | IVR BBB+ | — | Infomerics | ₹ 156.17 Cr. | |
| 27 Feb 2026 | ▲ Upgrade | IVR BBB+ | — | Infomerics | ₹ 156.17 Cr. |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 82 | 87 | 118 | 79 | 107 | 103 | 167 | 120 | 145 | 161 | 213 | 228 |
| Expenses | 72 | 76 | 107 | 68 | 93 | 89 | 150 | 103 | 123 | 135 | 184 | 195 |
| Operating Profit | 10 | 11 | 11 | 10 | 14 | 13 | 17 | 17 | 22 | 26 | 29 | 33 |
| OPM % | 12% | 12% | 9% | 13% | 13% | 13% | 10% | 14% | 15% | 16% | 14% | 14% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 3 | 4 | 4 | 4 | 5 | 5 | 8 | 7 | 8 | 11 | 14 | 9 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 4 |
| Profit before tax | 6 | 6 | 6 | 6 | 8 | 7 | 8 | 9 | 13 | 14 | 12 | 21 |
| Tax % | 32% | 27% | 13% | 25% | 44% | 25% | 12% | 25% | 25% | 25% | 4% | 36% |
| Net Profit | 4 | 4 | 5 | 4 | 4 | 5 | 7 | 7 | 10 | 10 | 11 | 13 |
| EPS in Rs | 2.79 | 2.99 | 3.59 | 2.91 | 3.01 | 3.75 | 4.98 | 4.77 | 6.85 | 6.51 | 6.75 | 7.98 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 31%
- 5 Years
- 37%
- 3 Years
- 32%
- TTM
- 50%
- 10 Years
- 40%
- 5 Years
- 75%
- 3 Years
- 45%
- TTM
- 90%
- 10 Years
- 67%
- 5 Years
- 62%
- 3 Years
- 63%
- TTM
- —
- 10 Years
- 14%
- 5 Years
- 15%
- 3 Years
- 15%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Fredun Pharmaceuticals | ₹ 1,473.00 | ₹ 2,242 Cr. | 57.5x | 8.3x | 16% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Daulat Nariman Medhora
- Executive Chairman of the Board, Joint Managing Director
- Fredun Nariman Medhora
- Chief Financial Officer, Managing Director, Executive Director
- Vaishnavi Sahu
- Compliance Officer, Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.